Syndrome with pulmonary hypertension as a major feature

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:275853
Who is this for?
Show terms as
1FDA treatments8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

"Syndrome with pulmonary hypertension as a major feature" is a grouping category used by Orphanet (ORPHA:275853) to classify rare genetic or developmental syndromes in which pulmonary hypertension (PH) is a prominent and defining clinical characteristic rather than a secondary or incidental finding. Pulmonary hypertension refers to abnormally elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. Over time, this increased pressure forces the right side of the heart to work harder, potentially leading to right heart failure. Patients may experience progressive shortness of breath, fatigue, chest pain, dizziness, and swelling in the legs or abdomen. Because this is a classification group rather than a single discrete disease entity, it encompasses multiple rare syndromes where pulmonary hypertension is a major defining feature. These may include conditions caused by mutations in genes such as BMPR2, EIF2AK4, TBX4, and others, each with distinct inheritance patterns and associated clinical findings. The body systems most commonly affected include the cardiovascular system (particularly the pulmonary vasculature and right heart), the respiratory system, and in some syndromic forms, the skeletal, immune, or hematologic systems. Treatment depends on the specific underlying syndrome and typically involves pulmonary vasodilator therapies such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin pathway agents. Supportive care including supplemental oxygen, diuretics, and anticoagulation may also be employed. In severe or refractory cases, lung transplantation may be considered. Early diagnosis and management by a multidisciplinary team including pulmonologists, cardiologists, and clinical geneticists is essential for optimizing outcomes.

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Dec 1999

INOmax: FDA approved

In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

INOmax

Nitric oxide· Mallinckrodt Hospital ProductsOrphan Drug
In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardi

In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

No actively recruiting trials found for Syndrome with pulmonary hypertension as a major feature at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Syndrome with pulmonary hypertension as a major feature community →

No specialists are currently listed for Syndrome with pulmonary hypertension as a major feature.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Syndrome with pulmonary hypertension as a major feature.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Syndrome with pulmonary hypertension as a major featureForum →

No community posts yet. Be the first to share your experience with Syndrome with pulmonary hypertension as a major feature.

Start the conversation →

Latest news about Syndrome with pulmonary hypertension as a major feature

No recent news articles for Syndrome with pulmonary hypertension as a major feature.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Syndrome with pulmonary hypertension as a major feature

What is Syndrome with pulmonary hypertension as a major feature?

"Syndrome with pulmonary hypertension as a major feature" is a grouping category used by Orphanet (ORPHA:275853) to classify rare genetic or developmental syndromes in which pulmonary hypertension (PH) is a prominent and defining clinical characteristic rather than a secondary or incidental finding. Pulmonary hypertension refers to abnormally elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. Over time, this increased pressure forces the right side of the heart to work harder, potentially leading to right heart failure. Patients may experience pro

What treatment and support options exist for Syndrome with pulmonary hypertension as a major feature?

1 patient support program are currently tracked on UniteRare for Syndrome with pulmonary hypertension as a major feature. See the treatments and support programs sections for copay assistance, eligibility, and contact details.